BrainChip (BRN.AX) ASX A$0.135 pre-market 14 Feb 2026: monitor Akida deals

We note BRN.AX stock trading at A$0.135 in pre-market trade on 14 Feb 2026 after a 1-day drop of -6.90%. Volume is elevated at 16,691,022.00 shares, above the 50-day average. Investors in BrainChip Holdings Ltd (BRN.AX) should watch near-term revenue catalysts tied to Akida product rollouts and the company earnings cycle as drivers of price moves.

BRN.AX stock current snapshot

BrainChip Holdings Ltd (BRN.AX) is priced at A$0.135 with a 1-day change of -6.90% and a trading range today of A$0.130 – A$0.145. Market capitalisation stands at A$318,391,868.00 and shares outstanding are 2,358,458,279.00.

Trading shows higher-than-normal activity today with volume 16,691,022.00 versus average volume 9,372,947.00. The 50-day average price is A$0.168 and the 200-day average is A$0.195, highlighting recent downside pressure versus the 12-month high of A$0.325 and low of A$0.130.

Earnings, valuation and financials for BRN.AX stock

Latest reported EPS is -0.02 and the trailing PE is -6.75, reflecting losses. Revenue per share is 0.000632 and net income per share is -0.010708. The company shows a strong liquidity position with a current ratio of 5.18 and cash per share of 0.006470.

BrainChip’s price-to-sales and price-to-book ratios are elevated at 184.34 and 14.03 respectively. Operating margins remain negative at -17.03%, and free cash flow per share is -0.007024. These metrics imply the stock trades on growth expectations rather than current profitability.

Technical signals and trading setup for BRN.AX stock

Technically the stock shows mixed momentum. RSI is 60.30, the CCI reads 137.05 (overbought), and the Money Flow Index is 86.99 (overbought). Bollinger bands currently sit at 0.150 lower and 0.190 upper, giving a measured range for intraday trade.

Short-term traders should note the Relative Volume of 1.71, indicating above-average activity. ADX is 19.05, which suggests no strong trend yet. Use tight risk controls: ATR is 0.01, so stops sized to that volatility make sense.

Meyka AI rates BRN.AX with a score out of 100

Meyka AI rates BRN.AX with a score of 64.77 out of 100 and assigns a Grade: B with a suggestion to HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects a 12-month price of A$0.166, compared with the current A$0.135, implying an upside of 23.14%. Forecasts are model-based projections and not guarantees. Visit our platform for live updates: BRN.AX on Meyka.

Risks and catalysts shaping BRN.AX stock

Key catalysts include Akida neuromorphic processor commercial deals, new OEM partnerships, and the upcoming earnings announcement on 4 Mar 2026. Positive contract news could lift sentiment and volume.

Risks include continued negative margins, high valuation multiples versus revenue, and liquidity-driven volatility. Sector pressure in semiconductors and broader tech sentiment on the ASX may amplify moves. Keep an eye on cash runway and customer adoption metrics.

Practical trading and investment outlook for BRN.AX stock

For AI-focused investors we view BrainChip as a high-beta play on edge-AI adoption. Short-term traders may work the intraday range between A$0.13 and A$0.19. A conservative 3-month price target from model signals is A$0.090 and a 12-month target is A$0.166 based on Meyka AI forecasts.

Position sizing should reflect the stock’s volatility and low per-share price. Institutional-style investors should wait for clearer revenue traction or improved operating margins before adding a core position.

Final Thoughts

BRN.AX stock trades at A$0.135 in pre-market on 14 Feb 2026, with above-average volume and mixed technical signals. The company remains a specialized AI and semiconductors play through its Akida neuromorphic products. Our Meyka AI grade is 64.77/100 (B, HOLD) and the platform’s 12-month forecast of A$0.166 implies ~23.14% upside from current levels. That upside is balanced by negative operating margins, high price-to-sales and price-to-book ratios, and earnings risk. Short-term traders can exploit volatility with tight stops. Longer-term investors should look for revenue milestones and repeatable OEM wins before increasing exposure. For live filings and company updates see the official site BrainChip website and company updates on Twitter. Meyka AI provides this AI-powered market analysis as informational research and not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.